The effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266271
Abstract: The efficacy of SARS-CoV-2 vaccines reported in Phase 3 trials varies from ~45% to ~95%. This study tests the hypothesis that the observed variation in efficacy of SARS-CoV-2 vaccine candidates can be explained by the… read more here.
Keywords: prevalence; cov vaccines; efficacy sars; pandemic prevalence ... See more keywords